Finasteride Monitoring Schedule: Labs & Exams Your Doctor Should Order

The one test the label schedules: PSA

For Propecia (1 mg), the warnings and precautions section covers PSA, high-grade prostate cancer risk and exposure of pregnant women, and it says two things about PSA: the drug lowers it, and any confirmed increase from the lowest value on treatment may signal prostate cancer and should be evaluated even if the number sits inside the normal range for untreated men [2].

The Proscar (5 mg) label gives the arithmetic. PSA falls by approximately 50% within six months, a new baseline should be established at least six months after starting with periodic monitoring after that, and an isolated PSA value in a man treated for six months or more should be doubled for comparison with normal ranges in untreated men [1].

How the PSA numbers behave

In men aged 18 to 41 taking Propecia, mean serum PSA fell from 0.7 ng/mL at baseline to 0.5 ng/mL at month 12 [2]. In older men with BPH on Proscar, the fall is around 50% within six months, and the label notes the reduction is predictable across the PSA range although it may vary between individuals [1].

The label adds two cautions. Finasteride can lower PSA even when prostate cancer is present, and missed doses may affect PSA results [1]. Percent free PSA is the exception: the free-to-total ratio stays constant and needs no adjustment [1].

The seven-year Prostate Cancer Prevention Trial enrolled 18,882 men aged 55 or older with a normal digital rectal exam and PSA of 3.0 ng/mL or less, who took finasteride 5 mg or placebo; biopsy was recommended if the annual PSA, adjusted for finasteride's effect, exceeded 4.0 ng/mL or if the rectal exam was abnormal [4]. Gleason 8 to 10 cancers were found in 1.8% of men taking finasteride 5 mg versus 1.1% of men taking placebo [1]. The label states that 5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer [1], and the clinical significance of that finding for men taking Propecia 1 mg is unknown [2].

Liver, hormones and blood counts

The warnings sections of the two labels cover PSA, high-grade prostate cancer risk, exposure of pregnant women, use in children and, for Proscar, other urological conditions; they set out no routine liver, kidney, hormone or blood-count panel [2][1]. Proscar does specify a new PSA baseline at least six months after starting and periodic PSA monitoring, and careful monitoring for obstructive uropathy in men with a large residual urine volume or severely diminished urinary flow, who the label says may not be candidates for finasteride [1]. Propecia says a confirmed PSA rise from the lowest value should be evaluated [2].

Finasteride is extensively metabolized in the liver, mainly by CYP3A4, into two metabolites with no more than 20% of its activity [2]. The interaction section reports no clinically important interactions and names the compounds tested in man: antipyrine, digoxin, propranolol, theophylline and warfarin [2].

The drug does shift androgen levels. A 1 mg tablet suppresses serum DHT by 65% within 24 hours, and mean testosterone and estradiol rise by about 15%, staying within the physiological range [2]. A 42-day dose-ranging study of 249 men with androgenetic alopecia measured serum DHT falls of 71.4% at 1 mg and 72.2% at 5 mg, with scalp DHT down 64.1% at 1 mg and 69.4% at 5 mg [5]. Those are measurements of drug effect, not monitoring targets in the label.

What the labels list as adverse effects

The 12-month controlled trials of Propecia enrolled 945 men on drug and 934 on placebo, aged 18 to 41. Drug-related decreased libido was reported in 1.8% versus 1.3%, erectile dysfunction in 1.3% versus 0.7%, and ejaculation disorder in 1.2% versus 0.7%; 3.8% of treated men reported one or more of these against 2.1% on placebo (p=0.04), and each individual rate fell to 0.3% or less by year five [2].

A meta-analysis of 15 randomized placebo-controlled trials covering 4,495 men with androgenetic alopecia put the relative risk of sexual dysfunction on finasteride 1 mg at 1.66 (95% CI 1.20 to 2.30) [6]. A separate review of 34 finasteride trials for hair loss found none with adequate safety reporting and funnel-plot asymmetry pointing to under-detection of sexual adverse effects [7].

The label's postmarketing section lists sexual dysfunction that continued after stopping, including erectile dysfunction, libido disorders, ejaculation disorders and orgasm disorders, along with male infertility and poor seminal quality, with normalization or improvement reported after discontinuation [2].

Depression, suicidal ideation and behavior appear in the same postmarketing section. There is no boxed warning on either product; the wording changed in August 2022 after an FDA safety labeling change order, and the label states these are voluntary reports from a population of uncertain size from which a causal relationship cannot reliably be established [3].

Breast tenderness, breast enlargement and male breast cancer are also postmarketing reports, and the label says the relationship between long-term finasteride use and male breast neoplasia is unknown [2]. Hypersensitivity reactions including rash, itching, hives and angioedema are listed as well [2].

On semen: 24 weeks of Proscar 5 mg in healthy volunteers produced no clinically meaningful effect on sperm concentration, motility, morphology or pH, but median ejaculate volume fell 0.6 mL (22.1%), reversible with an average 84 weeks to return to baseline [1]. With Propecia 1 mg, median ejaculate volume fell 0.3 mL (-11%) versus 0.2 mL (-8%) on placebo at 48 weeks [2].

How benefit is measured for hair loss and for BPH

Propecia is indicated for male pattern hair loss in men only, with efficacy in bitemporal recession not established [2]. Daily use for three months or more is usually needed before benefit appears, continued use is needed to sustain it, and stopping reverses the effect within 12 months [2]. In the two one-year vertex trials that enrolled 1,553 men aged 18 to 41, hair count in a 5.1 cm2 circle of vertex scalp (baseline 876 hairs) was 107 hairs higher than placebo at one year and 138 higher at two years [8]. HealthRX.com offers finasteride 1 mg by prescription.

Proscar 5 mg is for symptomatic BPH in men with an enlarged prostate [1]. In MTOPS, 3,047 men followed for a mean of 4.5 years had a 66% reduction in overall clinical progression on finasteride plus doxazosin versus placebo, and 34% on finasteride alone [9]. In the two-year PROWESS study, total symptom score fell 2.9 points versus 1.9 on placebo at 12 months, peak urinary flow rose 1.2 versus 0.6 mL/s, and prostate volume changed -14.2% versus +5.4% [10].

The PSA doubling formula is spelled out in the 5 mg label; the 1 mg label says PSA falls and that a confirmed rise from the lowest value should be evaluated, but gives no formula [2][1].